Despite the sloppy weather this morning, a great day in Boston at the Personalized Cancer Vaccine Conference presenting new data on our DPX platform supporting further differentiation from current aqueous, emulsion, and LNP antigen delivery systems.? https://lnkd.in/eE32AGS2
BioVaxys Technology Corp.
生物技术研究
Etobicoke，Ontario 482 位关注者
Antiviral and Anticancer Vaccine Platforms Harnessing the Power of T-Cells
关于我们
BioVaxys Technology Corp. (CSE:BIOV, OTCQB:BVAXF, FR:5LB), formerly BioVaxys LLC, is a British Columbia-registered clinical-stage biotechnology company dedicated to improving patient lives with novel immunotherapies based on our DPX? immune-educating delivery technology platform and our HapTenix? neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The Company’s clinical stage pipeline includes maveropepimut-S which is in Phase IIb clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using our proprietary HapTenix? neoantigen tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer. BioVaxys is capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens.
- 网站
-
https://www.biovaxys.com
BioVaxys Technology Corp.的外部链接
- 所属行业
- 生物技术研究
- 规模
- 2-10 人
- 总部
- Etobicoke，Ontario
- 类型
- 上市公司
- 创立
- 2020
- 领域
- Oncology、Biotechnology、Melanoma、Ovarian Cancer、Cancer Vaccines、Immunotherapeutics、Cancer、Vaccine、virology、Personalized Immunotherapy、lipid delivery和drug delivery
地点
BioVaxys Technology Corp.员工
动态
-
BioVaxys animal health partner SpayVac-for-Wildlife, Inc., ramps up production of SpayVac, its immunocontraceptive vaccine based on BioVaxys technology, in preparation for launch in the near future https://lnkd.in/eVY8uVj7
-
https://lnkd.in/egqAb2zY We are extremely pleased to have Dr. Raj Rajagopalan joining the BioVaxys team to support our DPX formulation capabilities.
-
$BIOV $BVAXF presenting this Thursday Sept 19th, 11:30AM EST, at the Life Sciences Investor Forum @RIConferences. We invite you to attend the presentation via the following link: https://bit.ly/3XjDJkL https://lnkd.in/e4qA2K9p
-
The agenda has officially been released for the Personalized Cancer Vaccine Summit, formerly known as the mRNA Cancer Vaccine Summit, arriving in Boston this December 3-5! Discover the brand-new full event guide here > https://ter.li/jc0d4q Join expert leaders from BioNTech SE, Geneos Therapeutics, BioVaxys Technology Corp., CureVac, Imvax, Inc., Nouscom and more at the only conference uniting biopharma companies working on different vaccine modalities to develop an immune-responsive personalized cancer vaccine for one goal - cure cancer! Download the agenda to discover what topics we will explore this year: https://ter.li/d00v8y #mRNA #CancerVaccine #PersonalizedCancerVaccine #Vaccine
-
-
https://lnkd.in/eNT3ZtV4 DPX, our immune educating platform, can play a major role in developing more effective viral vaccines, such as multivalent mRNA DTP and multivalent flu, and vaccines for emerging global diseases such as Zika and MPox.
-
https://lnkd.in/ejHGf6si Congratulations to our technology licensee, SpayVac-for-Wildlife, Inc., on the completion of its new R&D and production facility for their long duration,, single dose, immunocontraception vaccine for fertility-control needs in wildlife, agricultural production animals, and aquaculture markets. #immunocontraception #vaccines #animalhealth #antigen #lipiddelivery
-
https://lnkd.in/ehGf5jCV If you have not yet seen the announcement, we upsized the private placement. If anyone is interested in participating, please message me on LinkedIn or send us a message directly from our website info request form.
-
This is a potential game changer. People with life threatening nut allergies, and parents of children with life threatening nut allergies, live on a knife edge with the constant possibility of cross contamination or accidential exposure. Many of us at BioVaxys and AP Visionaries have family members for whom this is a daily reality. Our ability to tackle this unmet medical need directly attributable to the immune educating capability and highly flexible antigen loading capacity of our DPX? platform. https://lnkd.in/engG4Dsg
-
https://lnkd.in/gVHNnwCg Congratulations to our friends and colleagues at SpayVac-for-Wildlife Inc. for their immunocontraception study in Thailand utilizing our patented liposome-based antigen delivery platform technology.